We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avadel Pharmaceuticals (AVDL - Free Report) recently announced that its board of directors has decided that Lundbeck’s unsolicited offer to buy the latter made on Nov. 13, 2025, is a “Company Superior Proposal” based on the terms of the current agreement with Alkermes (ALKS - Free Report) .
More on AVDL's Latest Offer From Lundbeck
Denmark-based H. Lundbeck A/S made an unsolicited offer to acquire Ireland-based Avadel for up to $23.00 per share, valuing it at about $2.4 billion. The bid reflects a roughly 29% premium to Avadel’s closing price on Oct. 21, 2025, the last trading day before the Alkermes deal was announced.
Last month, Alkermes announced a definitive agreement to acquire Avadel in a deal valued at up to $20.00 per share in cash, representing a total transaction value of around $2.1 billion.
Year to date, shares of Avadel have soared 119% compared with the industry’s rise of 6.4%.
Image Source: Zacks Investment Research
Lundbeck is looking to buy Avadel for up to $23.00 per share, including $21.00 in cash plus a non-transferable contingent value right that could pay an extra $1.00 if Lumryz and valiloxybate reach $450 million in annual net sales in the United States by 2027 and another $1.00 if they reach $700 million by 2030.
The deal is subject to customary closing conditions, including approval from Avadel shareholders and regulators.
Avadel’s lead commercial product Lumryz is approved as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy.
As of Sept. 30, 2025, around 3,400 patients were on Lumryz therapy. In the first nine months of 2025, Lumryz generated sales worth $198.1 million, reflecting an increase of almost 67% on a year-over-year basis.
AVDL's Recent Development With ALKS
Following the unsolicited acquisition proposal from Lundbeck, Avadel has informed Alkermes that it considers the former’s offer to be a Company Superior Proposal. This notice activates a five-business-day window in which Alkermes can, if it chooses, negotiate with Avadel to revise the acquisition proposal so that Lundbeck’s bid would no longer be deemed superior.
At present, the agreement with Alkermes remains active and Avadel’s board has not withdrawn its support for the Alkermes deal.
However, once the five business days are over, Avadel, with advice from the financial and legal teams and after considering any changes Alkermes proposes, still determines that Lundbeck’s offer is superior and that failing to act would breach the fiduciary responsibilities, it may terminate the agreement with ALKS.
It can be inferred that presently, Lundbeck’s offer to buy Avadel outbids that of Alkermes.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have increased from $1.52 to $2.90. Earnings per share estimates for 2026 have moved up from $2.09 to $2.72 during the same period. CRMD stock has surged 23.2% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 27.04%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from 65 cents to 23 cents. Loss per share estimates for 2026 have narrowed from $2.10 to $1.42 during the same period. CSTL stock has rallied 27.4% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with an average surprise of 66.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
Key Takeaways
Avadel Pharmaceuticals (AVDL - Free Report) recently announced that its board of directors has decided that Lundbeck’s unsolicited offer to buy the latter made on Nov. 13, 2025, is a “Company Superior Proposal” based on the terms of the current agreement with Alkermes (ALKS - Free Report) .
More on AVDL's Latest Offer From Lundbeck
Denmark-based H. Lundbeck A/S made an unsolicited offer to acquire Ireland-based Avadel for up to $23.00 per share, valuing it at about $2.4 billion. The bid reflects a roughly 29% premium to Avadel’s closing price on Oct. 21, 2025, the last trading day before the Alkermes deal was announced.
Last month, Alkermes announced a definitive agreement to acquire Avadel in a deal valued at up to $20.00 per share in cash, representing a total transaction value of around $2.1 billion.
Year to date, shares of Avadel have soared 119% compared with the industry’s rise of 6.4%.
Image Source: Zacks Investment Research
Lundbeck is looking to buy Avadel for up to $23.00 per share, including $21.00 in cash plus a non-transferable contingent value right that could pay an extra $1.00 if Lumryz and valiloxybate reach $450 million in annual net sales in the United States by 2027 and another $1.00 if they reach $700 million by 2030.
The deal is subject to customary closing conditions, including approval from Avadel shareholders and regulators.
Avadel’s lead commercial product Lumryz is approved as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy.
As of Sept. 30, 2025, around 3,400 patients were on Lumryz therapy. In the first nine months of 2025, Lumryz generated sales worth $198.1 million, reflecting an increase of almost 67% on a year-over-year basis.
AVDL's Recent Development With ALKS
Following the unsolicited acquisition proposal from Lundbeck, Avadel has informed Alkermes that it considers the former’s offer to be a Company Superior Proposal. This notice activates a five-business-day window in which Alkermes can, if it chooses, negotiate with Avadel to revise the acquisition proposal so that Lundbeck’s bid would no longer be deemed superior.
At present, the agreement with Alkermes remains active and Avadel’s board has not withdrawn its support for the Alkermes deal.
However, once the five business days are over, Avadel, with advice from the financial and legal teams and after considering any changes Alkermes proposes, still determines that Lundbeck’s offer is superior and that failing to act would breach the fiduciary responsibilities, it may terminate the agreement with ALKS.
It can be inferred that presently, Lundbeck’s offer to buy Avadel outbids that of Alkermes.
Avadel Pharmaceuticals PLC. Price
Avadel Pharmaceuticals PLC. price | Avadel Pharmaceuticals PLC. Quote
AVDL's Zacks Rank & Stocks to Consider
Avadel currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have increased from $1.52 to $2.90. Earnings per share estimates for 2026 have moved up from $2.09 to $2.72 during the same period. CRMD stock has surged 23.2% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 27.04%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from 65 cents to 23 cents. Loss per share estimates for 2026 have narrowed from $2.10 to $1.42 during the same period. CSTL stock has rallied 27.4% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with an average surprise of 66.11%.